Integer Holdings Corp is a leading provider of advanced medical devices and components, specializing in the design and manufacture of innovative solutions for the healthcare industry
The company focuses on developing products that support critical therapeutic and diagnostic applications, catering to a diverse range of medical markets including cardiovascular, orthopedics, and neuromodulation. Integer's expertise encompasses a variety of technologies, enabling it to deliver high-quality, reliable medical products that enhance patient outcomes and drive advancements in healthcare. Through strategic partnerships and a commitment to innovation, Integer Holdings Corp plays a vital role in improving lives and expanding the possibilities of medical technology.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQSTAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Medical technology company Integer Holdings (NYSEITGR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 11.1% year on year to $449.5 million. The company’s full-year revenue guidance of $1.86 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.43 per share was 2% below analysts’ consensus estimates.
Truist Securities initiates coverage on Integer. With a Buy rating and a $137 target, Integer is poised for significant gains driven by organic growth and strategic acquisitions.
BofA Securities' upgrades Integer, highlighting the growth potential of pulsed field ablation (PFA) in atrial fibrillation treatment. With projections of PFA sales skyrocketing from $100-200 million in 2023 to over $2 billion in 2025, Integer emerges as a key supplier for major PFA device manufacturers
